Grace Therapeutics
GRCE
13 hedge funds and large institutions have $577K invested in Grace Therapeutics in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.18% less ownership
Funds ownership: 0.23% → 0.04% (-0.18%)
7% less funds holding
Funds holding: 14 → 13 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
63% less capital invested
Capital invested by funds: $1.55M → $577K (-$972K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$159K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$48.3K |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$27.8K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$5.13K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$4.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$528K |
| 2 |
Renaissance Technologies
New York
|
-$273K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$238K |
| 4 |
VF
Virtu Financial
New York
|
-$121K |
| 5 |
IIM
Intact Investment Management
Montreal,
Quebec, Canada
|
-$41.1K |
GRCE Hedge Fund Activity: Q1 2018 in Review
13 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2018, worth a combined $577K — down 63% from $1.55M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GRCE and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Bank of Montreal, adding an estimated $159K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $528K sold.
- 13 institutional investors held Grace Therapeutics (GRCE) as of Q1 2018, down from 14 in Q4 2017.
- Funds reported $577K of Grace Therapeutics stock for Q1 2018, down 63% quarter-over-quarter.
- 3 funds opened new Grace Therapeutics positions in Q1 2018 and 4 closed out, a net change of -1 holder.
- The largest Grace Therapeutics buyer in Q1 2018 was Bank of Montreal, an estimated $159K added.
- The largest Grace Therapeutics seller in Q1 2018 was Susquehanna International Group, an estimated $528K sold.
Based on aggregated 13F filings for Q1 2018.